TVTX

+ Watchlist + Portfolio

Travere Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $65.96
52-Week Range: $17.05 – $66.24
Market Cap: $6.08B
P/E (TTM): —
EPS (TTM): -0.72
Dividend Yield: —

Advanced Metrics

Price/Book: 60.36
PEG Ratio: —
Return on Equity: -236.36%
Return on Assets: -3.73%
Gross Margin: 59.21%
Operating Margin: 2.33%
Profit Margin: -7.35%
Current Ratio: 4.05
Debt/Equity: 25.16
Total Debt: $616.91M
Free Cash Flow: $-18.25M
Revenue Growth: 48.20%
Earnings Growth: —
Enterprise Value: $6.20B

TVTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$109.46M	$145.24M	$233.18M	$490.73M
Cost of Revenue	$4.42M	$11.45M	$7.74M	$10.34M
Gross Profit	$105.04M	$133.79M	$225.43M	$480.39M
Research & Development	$227.33M	$244.99M	$282.70M	$206.01M
Selling, General & Admin	$197.52M	$265.54M	$264.12M	$337.20M
Operating Expenses	$424.85M	$510.53M	$546.82M	$543.21M
Operating Income	-$319.81M	-$376.74M	-$321.39M	-$62.82M
EBITDA	-$299.42M	-$326.25M	-$265.77M	$22.22M
Pretax Income	-$331.15M	-$376.11M	-$320.51M	-$49.27M
Income Tax	$313.00K	$223.00K	$120.00K	$988.00K
Net Income	-$278.48M	-$111.40M	-$321.55M	-$25.55M
Diluted EPS	-4.37	-1.50	-4.08	-0.29
Diluted Shares	63.76M	74.27M	78.89M	89.21M

TVTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$61.69M	$58.18M	$58.53M	$93.03M
Receivables	$16.65M	$21.18M	$27.12M	$80.13M
Inventory	$4.52M	$9.41M	$6.20M	$5.88M
Current Assets	$486.44M	$616.77M	$416.70M	$437.56M
Total Assets	$672.59M	$788.91M	$594.13M	$605.19M
Current Liabilities	$142.16M	$177.91M	$200.75M	$159.90M
Long-Term Debt	$375.55M	$377.26M	$310.31M	$311.72M
Total Debt	$407.49M	$404.78M	$401.58M	$328.73M
Total Liabilities	$629.73M	$588.10M	$535.05M	$490.36M
Retained Earnings	-$1.01B	-$1.13B	-$1.45B	-$1.47B
Shareholders' Equity	$42.85M	$200.81M	$59.08M	$114.83M
Working Capital	$344.27M	$438.87M	$215.95M	$277.66M
Net Debt	$313.86M	$319.09M	$320.45M	$218.69M

TVTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$186.29M	-$280.02M	-$237.47M	$37.78M
Capital Expenditure	-$28.37M	-$41.59M	-$101.21M	-$58.16M
Free Cash Flow	-$214.66M	-$321.61M	-$338.69M	-$20.37M
Depreciation & Amortisation	$20.72M	$38.53M	$43.55M	$60.74M
Stock-Based Compensation	$38.14M	$44.25M	$36.91M	$44.87M
Investing Cash Flow	-$32.55M	$55.78M	$99.33M	$27.89M
Financing Cash Flow	$117.57M	$218.75M	$139.42M	-$33.47M
Net Change in Cash	-$101.27M	-$5.49M	$1.27M	$32.21M

TVTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$81.73M	$114.45M	$164.86M	$129.69M	$127.20M
Cost of Revenue	$17.10M	$1.52M	$1.58M	$2.55M	$26.77M
Gross Profit	$64.63M	$112.93M	$163.27M	$127.14M	$100.43M
Research & Development	$46.89M	$49.36M	$51.89M	$57.87M	$57.09M
Selling, General & Admin	$60.41M	$76.22M	$86.45M	$101.69M	$80.25M
Operating Expenses	$107.30M	$125.58M	$138.34M	$159.56M	$137.35M
Operating Income	-$42.67M	-$12.65M	$24.93M	-$32.43M	-$36.91M
EBITDA	-$25.53M	$4.13M	$44.25M	-$632.00K	-$9.21M
Pretax Income	-$41.19M	-$12.73M	$25.71M	-$21.07M	-$36.72M
Income Tax	$39.00K	$20.00K	$8.00K	$921.00K	-$120.00K
Net Income	-$41.23M	-$12.76M	$25.71M	$2.73M	-$37.10M
Diluted EPS	-0.47	-0.14	0.28	0.03	-0.40
Diluted Shares	88.36M	88.95M	102.62M	90.29M	91.87M

TVTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$61.90M	$75.15M	$110.93M	$93.03M	$78.36M
Receivables	$34.38M	$38.72M	$82.98M	$80.13M	$87.30M
Inventory	$3.93M	$4.09M	$5.55M	$5.88M	$6.36M
Current Assets	$374.17M	$379.57M	$371.11M	$437.56M	$392.68M
Total Assets	$548.80M	$555.31M	$538.58M	$605.19M	$555.19M
Current Liabilities	$182.46M	$189.54M	$135.07M	$159.90M	$125.44M
Long-Term Debt	$310.66M	$311.02M	$311.37M	$311.72M	$312.08M
Total Debt	$400.46M	$399.57M	$329.75M	$328.73M	$327.66M
Total Liabilities	$515.98M	$522.56M	$465.02M	$490.36M	$456.46M
Retained Earnings	-$1.49B	-$1.50B	-$1.48B	-$1.47B	-$1.51B
Shareholders' Equity	$32.82M	$32.75M	$73.56M	$114.83M	$98.73M
Working Capital	$191.71M	$190.03M	$236.04M	$277.66M	$267.24M
Net Debt	$317.52M	$304.70M	$200.44M	$218.69M	$233.72M

TVTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$42.19M	$4.98M	$14.32M	$60.68M	-$40.37M
Capital Expenditure	-$11.78M	-$12.32M	-$15.19M	-$18.86M	-$22.18M
Free Cash Flow	-$53.98M	-$7.34M	-$871.00K	$41.81M	-$62.54M
Depreciation & Amortisation	$12.80M	$14.02M	$15.79M	$18.14M	$25.21M
Stock-Based Compensation	$11.49M	$10.65M	$11.26M	$11.46M	$16.15M
Investing Cash Flow	$41.29M	$4.85M	$86.59M	-$104.84M	$21.55M
Financing Cash Flow	$3.72M	$1.48M	-$65.34M	$26.68M	$4.20M
Net Change in Cash	$2.81M	$11.31M	$35.57M	-$17.48M	-$14.61M

Market Snapshot

About

Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases. The company has a commercial product for the treatment of IgA nephropathy and a pipeline of investigational therapies. Travere is committed to advancing treatments for patients with high unmet medical needs in rare diseases.